Induction and Characterization of Pulmonary Hypertension in Mice using the Hypoxia/SU5416 Model

被引:5
|
作者
Bikou, Olympia [1 ]
Hajjar, Roger J. [2 ]
Hadri, Lahouaria [1 ]
Sassi, Yassine [1 ]
机构
[1] Icahn Sch Med Mt Sinai, Cardiovasc Res Ctr, New York, NY 10029 USA
[2] Phospholamban Fdn, New York, NY USA
来源
基金
美国国家卫生研究院;
关键词
Medicine; Issue; 160; Hypoxia; SU5416; Sugen; pulmonary hypertension; PH; right ventricular pressure; pulmonary vascular remodeling; right ventricular remodeling; 5416/HYPOXIA MOUSE MODEL; ARTERIAL-HYPERTENSION; ANIMAL-MODELS;
D O I
10.3791/59252
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Pulmonary Hypertension (PH) is a pathophysiological condition, defined by a mean pulmonary arterial pressure exceeding 25 mm Hg at rest, as assessed by right heart catheterization. A broad spectrum of diseases can lead to PH, differing in their etiology, histopathology, clinical presentation, prognosis, and response to treatment. Despite significant progress in the last years, PH remains an uncured disease. Understanding the underlying mechanisms can pave the way for the development of new therapies. Animal models are important research tools to achieve this goal. Currently, there are several models available for recapitulating PH. This protocol describes a two-hit mouse PH model. The stimuli for PH development are hypoxia and the injection of SU5416, a vascular endothelial growth factor (VEGF) receptor antagonist. Three weeks after initiation of Hypoxia/SU5416, animals develop pulmonary vascular remodeling imitating the histopathological changes observed in human PH (predominantly Group 1). Vascular remodeling in the pulmonary circulation results in the remodeling of the right ventricle (RV). The procedures for measuring RV pressures (using the open chest method), the morphometrical analyses of the RV (by dissecting and weighing both cardiac ventricles) and the histological assessments of the remodeling (both pulmonary by assessing vascular remodeling and cardiac by assessing RV cardiomyocyte hypertrophy and fibrosis) are described in detail. The advantages of this protocol are the possibility of the application both in wild type and in genetically modified mice, the relatively easy and low-cost implementation, and the quick development of the disease of interest (3 weeks). Limitations of this method are that mice do not develop a severe phenotype and PH is reversible upon return to normoxia. Prevention, as well as therapy studies, can easily be implemented in this model, without the necessity of advanced skills (as opposed to surgical rodent models).
引用
收藏
页码:1 / 9
页数:9
相关论文
共 50 条
  • [21] Pneumonectomy combined with SU5416 induces severe pulmonary hypertension in rats
    Happe, C. M.
    de Raaf, M. A.
    Rol, N.
    Schalij, I.
    Vonk-Noordegraaf, A.
    Westerhof, N.
    Voelkel, N. F.
    de Man, F. S.
    Bogaard, H. J.
    AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2016, 310 (11) : L1088 - L1097
  • [22] Upregulation of Aquaporin 1 Mediates Increased Migration and Proliferation in Pulmonary Vascular Cells From the Rat SU5416/Hypoxia Model of Pulmonary Hypertension
    Yun, Xin
    Philip, Nicolas M.
    Jiang, Haiyang
    Smith, Zion
    Huetsch, John C.
    Damarla, Mahendra
    Suresh, Karthik
    Shimoda, Larissa A.
    FRONTIERS IN PHYSIOLOGY, 2021, 12
  • [23] Amelioration Of Su5416/hypoxia-Induced Pulmonary Hypertension Following Treatment With Emapii-Neutralizing Antibodies
    Clauss, M.
    Bednorz, M.
    Green, L.
    Yi, R.
    Seimetz, M.
    Petrache, I.
    Lahm, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [24] Effect of T-Cell Activity on Susceptibility of Mice for Development of Severe Pulmonary Arterial Hypertension in Response to SU5416 and Chronic Hypoxia
    Taha, Mohamad
    Jiang, Baohua
    Deng, Yupu
    Stewart, Duncan
    CIRCULATION, 2012, 126 (21)
  • [25] Strain-specific Differences in the Response to SU5416 in the Rat Model of Severe Pulmonary Arterial Hypertension
    Jiang, BaoHua
    Deng, Yupu
    Taha, Mohamad
    Wen, Sophie
    Courtman, David W.
    Stewart, Duncan J.
    CIRCULATION, 2013, 128 (22)
  • [26] Marked Strain-Specific Differences in the SU5416 Rat Model of Severe Pulmonary Arterial Hypertension
    Jiang, Baohua
    Deng, Yupu
    Suen, Colin
    Taha, Mohamad
    Chaudhary, Ketul R.
    Courtman, David W.
    Stewart, Duncan J.
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2016, 54 (04) : 461 - 468
  • [27] Perinatal hypoxia aggravates occlusive pulmonary vasculopathy in SU5416/hypoxia-treated rats later in life
    Oshita, Hironori
    Sawada, Hirofumi
    Mitani, Yoshihide
    Tsuboya, Naoki
    Kabwe, Jane C.
    Maruyama, Junko
    Yusuf, Ali
    Ito, Hiromasa
    Okamoto, Ryuji
    Otsuki, Shoichiro
    Yodoya, Noriko
    Ohashi, Hiroyuki
    Oya, Kazunobu
    Kobayashi, Yuhko
    Kobayashi, Issei
    Dohi, Kaoru
    Nishimura, Yuhei
    Saitoh, Shinji
    Maruyama, Kazuo
    Hirayama, Masahiro
    AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2022, 323 (02) : L178 - L192
  • [28] Detrimental Impact of Vasopressin V2 Receptor Antagonism in a SU5416/Hypoxia/Normoxia-Exposed Rat Model of Pulmonary Arterial Hypertension
    Goto, Itaru
    Dohi, Kaoru
    Ogihara, Yoshito
    Okamoto, Ryuji
    Yamada, Norikazu
    Mitani, Yoshihide
    Ito, Masaaki
    CIRCULATION JOURNAL, 2016, 80 (04) : 989 - +
  • [29] Fasudil Dichloroacetate Alleviates SU5416/Hypoxia-Induced Pulmonary Arterial Hypertension by Ameliorating Dysfunction of Pulmonary Arterial Smooth Muscle Cells
    Liu, Ping
    Huang, Wen
    Ding, Yirui
    Wu, Jianbing
    Liang, Zhuangzhuang
    Huang, Zhangjian
    Xie, Weiping
    Kong, Hui
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 1653 - 1666
  • [30] Gb002, A Novel Inhaled Pdgfr Kinase Inhibitor, Demonstrates Efficacy in the Su5416 Hypoxia Rat Model of Pulmonary Arterial Hypertension (pah)
    Galkin, Anna
    Clemons, Bryan
    Garcia, Eduardo
    Brooks, Jennifer
    Slee, Debbie
    Salter-Cid, Luisa
    Zisman, Larry
    CIRCULATION, 2019, 140